Whalesbook
FY26 Financial Highlights
Accretion Nutraveda Ltd has announced its audited financial outcomes for the fiscal year that concluded on March 31, 2026. The company reported a Profit After Tax (PAT) of ₹5.07 crore, generated from revenue from operations amounting to ₹33.60 crore. This performance includes basic Earnings Per Share (EPS) of ₹9.35 on a consolidated basis.
Board and Governance Update
The company's board has seen significant changes. Two independent directors, Mr. Arun Dash and Mr. Mahipal Singh Chouhan, have tendered their resignations. The company has proposed Mr. Chand Rameshbhai Kanabar and Ms. Grishma A Shewale as new Additional Non-Executive, Independent Directors. Their appointments are subject to shareholder approval.
Audit Oversight for FY27
For the upcoming fiscal year, FY27, M/s. Sakhiya & Co. have been re-appointed as Secretarial Auditors. M/s. UMT & Co. will serve as the Internal Auditors, ensuring continued audit oversight.
Company Background and IPO Context
Accretion Nutraveda went public via an Initial Public Offering (IPO) in late December 2023, successfully raising ₹24.77 crore. The company operates in the nutraceutical and health supplement manufacturing and marketing sector, also providing contract manufacturing services.
IPO Fund Utilization
As of March 31, 2026, the company had utilized ₹18.21 crore of its IPO proceeds, leaving ₹6.55 crore unutilized.
Key Factors to Monitor
A key upcoming event for investors will be the shareholder vote on the new director appointments. Monitoring the efficient use of the remaining IPO funds in FY27 will also be crucial for future growth.
Peer Landscape
Accretion Nutraveda operates in the competitive health and wellness market. Its competitors include established players such as Zydus Wellness, known for its branded health foods, Vita Life Sciences, which focuses on nutraceuticals and dietary supplements, and Nureca Ltd, offering a diverse range of health and wellness products.